Company / Working Capital
Aclaris Therapeutics, Inc. Working Capital History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$67.7M
FY2025
5-year range
$67.7M / $209.6M
FY2021-FY2025
Trend
-28.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 3 consecutive years, from $210M in FY2022 to $68M in FY2025.
Based on SEC 10-K filings.
$68M in FY2025 with a 5-year CAGR of +9.7%.
Declined from $98M to $68M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -31.4%
- 5-Year CAGR
- +9.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Aclaris Therapeutics, Inc.'s working capital has declined for 3 consecutive years.
- 5-year CAGR of +9.7%, indicating consistent growth.
- In FY2025, working capital decreased 28.3% year-over-year.
- Peak working capital was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $67.7M | -28.3% |
| FY2024 | $94.4M | -3.6% |
| FY2023 | $97.9M | -53.3% |
| FY2022 | $209.6M | +15.1% |
| FY2021 | $182.1M | +327.3% |
| FY2020 | $42.6M | -30.6% |
| FY2019 | $61.4M | -59.7% |
| FY2018 | $152.2M | -18.8% |
| FY2017 | $187.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026